Drug Topics
SEPTEMBER 6, 2022
Improved glycemic control could reduce the risk of diabetes-related brain damage among teens and adolescents with type 1 diabetes.
PharmaVoice
SEPTEMBER 6, 2022
From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
SEPTEMBER 6, 2022
Pharmacist roles are explored as the panel discusses the anticipation of the coming flu season.
PharmaVoice
SEPTEMBER 6, 2022
With his unique platform, the has built a bridge between patients, physicians and researchers around the world.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
SEPTEMBER 6, 2022
Expert panelists share their thoughts on how to effectively educate patients on the efficacy of influenza vaccines.
PharmaVoice
SEPTEMBER 6, 2022
As a patient advocate, The Spark Global’s owner is transforming how pharma companies approach patient centricity.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
PharmaVoice
SEPTEMBER 6, 2022
Real-world data (RWD) from clinical drug registries can and should be used throughout the drug development lifecycle. At all stages, registries ensure that assumptions about the current standard of care are accurate and evidence-based.
Pharmacy Times
SEPTEMBER 6, 2022
Cognitive harm appears reversible, results of analysis by Nemours Children’s Health Jacksonville and Stanford University shows.
PharmaVoice
SEPTEMBER 6, 2022
The CMO at Kura Oncology, a clinical-stage biopharma company, is charting a new course to deliver on the promise of precision medicine in oncology.
STAT
SEPTEMBER 6, 2022
WASHINGTON — Researchers studying next-generation vaccines to fight an evolving Covid-19 threat are running into problems getting existing vaccines to use in their research. Because Pfizer and Moderna hold the patents for the current vaccines, researchers would likely have to get the companies’ permission to use them for research into products like nasal or pan-coronavirus vaccines.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmaVoice
SEPTEMBER 6, 2022
GSK’s medical oncology head is paving the way for patient-driven drug development and more equitable care.
Pharmacy Times
SEPTEMBER 6, 2022
Analysis shows that over 5 years, the percentage of women without relapse was 89% for those who had hormonal stimulation of the ovaries and 83% for those with ovarian tissue freezing.
PharmaVoice
SEPTEMBER 6, 2022
The longtime regulatory pro has used innovative strategies to deliver emerging oncology therapies to patients from her position as head of regulatory affairs at Stemline.
Pharmacy Times
SEPTEMBER 6, 2022
Patients with chronic migraines and higher frequencies of pain experienced the lowest vitamin B12 levels compared with patients with less frequent or no headache symptoms.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmaVoice
SEPTEMBER 6, 2022
The CEO of Evelo Biosciences is going where no one else in biotech has gone before.
Pharmacy Times
SEPTEMBER 6, 2022
A new statement from the American Heart Association stresses withdrawal medications and special care teams to prevent endocarditis in these individuals.
PharmaVoice
SEPTEMBER 6, 2022
The chief medical officer at physIQ is working at the intersection of healthcare, clinical trials and technology to deliver better, faster and more accurate treatments to patients around the globe.
Pharmacy Times
SEPTEMBER 6, 2022
Flublok Quadrivalent and Fluzone High-Dose Quadrivalent are both proven to prevent more cases in older adults compared with a standard-dose vaccine in randomized controlled trials.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmaVoice
SEPTEMBER 6, 2022
The COO has launched two jewels in the biotech world that complement each other while serving broader innovation goals throughout the industry.
STAT
SEPTEMBER 6, 2022
Tuberculosis kills 1.4 million people every year, primarily in places where poverty and deprivation conspire to make people uniquely vulnerable, and unable to get lifesaving care in time. Google is now joining a global fight to snuff out the disease, using AI to automate its detection — and expedite treatment — in communities where physicians are in short supply.
PharmaVoice
SEPTEMBER 6, 2022
The CEO of Alnylam — a leader in RNAi therapies — has the company at the top of its game scientifically and culturally.
STAT
SEPTEMBER 6, 2022
In a long-overdue move, the federal Office of Science and Technology Policy has issued guidance on making federally supported research and publications available to all without delay or embargo. This remarkable announcement about open access has the potential to remove information barriers that have long held back social and scientific progress. Even with immediate open access to research results, however, people with disabilities face unique barriers to information access.
pharmaphorum
SEPTEMBER 6, 2022
New UK Prime Minister Liz Truss needs to take immediate action to prevent the NHS spiralling out of control this winter, according to groups representing healthcare workers. Truss takes power as the NHS is in “its worst state in living memory,” according to NHS Confederation chief executive Matthew Taylor, who says it is vital that the health service becomes a “top three” priority for the new administration as it grapples with an estimated real-terms funding cut of £9.4 b
STAT
SEPTEMBER 6, 2022
“You would really benefit from hearing aids, but they aren’t covered by Medicare and cost around $4,000.” We’ve each said this phrase countless times to patients with hearing loss and are prepared for the reaction that invariably follows: an expression of bewilderment about why a pair of hearing aids may have to be their third largest material purchase in life, after a house and car.
NF2 BioSolutions
SEPTEMBER 6, 2022
Many of you already know Oscar and his story, but for those who don’t here goes! Oscar is 11, has just embarked on his next chapter starting secondary school. He inherited NF2 from his mum, Jo and was diagnosed about 5 years ago, mainly due to problems he was experiencing in his left foot. So since he got on the merry go round, we know Oscar has bilateral vestibular schwannoma and a frontal lobe meningioma in his head.
STAT
SEPTEMBER 6, 2022
Buzzy, venture-backed startups and big tech companies that have promised to disrupt health care are indeed doing so — including by shuttering services that early adopter patients may have come to rely on. Following its deal to acquire primary care tech company One Medical , Amazon announced it was ending its own virtual- and in-person health service Amazon Care , which covers 40,000 patients, by the end of the year.
Drug Store News
SEPTEMBER 6, 2022
The bivalent vaccines have been authorized for use as a single booster dose at least two months after primary or booster vaccination.
Pharmaceutical Technology
SEPTEMBER 6, 2022
The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group’s lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma. Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin. This approach aids the therapy to be activated mainly in the tumour, sparing healthy tissue from exposure.
Drug Store News
SEPTEMBER 6, 2022
In 2022, Signify Health's clinicians expect to connect with nearly 2.5 million unique members in-person and virtually.
PioneerRx
SEPTEMBER 6, 2022
There are so many things that go into an independent pharmacy’s success: the quality of patient care, the range (or lack) of clinical services you provide, the.
Drug Store News
SEPTEMBER 6, 2022
The bivalent vaccines have been authorized for use as a single booster dose at least two months after primary or booster vaccination.
Outsourcing Pharma
SEPTEMBER 6, 2022
Bioprocessing 4.0 and digitalization is all about embracing new technologies to enable faster, smoother and more efficient biomanufacturing. And that also requires embracing a new mindset.
Drug Store News
SEPTEMBER 6, 2022
David Petrie is joining the board and Ian Scholes, deputy chair, will retire from the board at the end of September.
Expert insights. Personalized for you.
469 
Let's personalize your content